Literature DB >> 15239141

Omega-3 fatty acids improve liver and pancreas function in postoperative cancer patients.

Axel R Heller1, Thomas Rössel, Birgit Gottschlich, Oliver Tiebel, Mario Menschikowski, Rainer J Litz, Thomas Zimmermann, Thea Koch.   

Abstract

Epidemiologic studies have indicated that high intake of saturated fat and/or animal fat increases the risk of colon and breast cancer. Omega-3 PUFAs in fish oil (FO) can inhibit the growth of human cancer cells in vitro and in vivo. These effects are related to the uptake of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) into the cellular substrate pool and their competitive metabolism with arachidonic acid (AA) at the cyclooxygenase and 5-lipoxygenase levels. The metabolites of EPA and DHA have less inflammatory and immunosuppressant potency than the substances derived from AA. Based on previous experimental data, we hypothesized that FO supplementation after major abdominal cancer surgery would improve hepatic and pancreatic function. Ours was a prospective, randomized, double-blinded clinical trial on 44 patients undergoing elective major abdominal surgery, randomly assigned to receive total parenteral nutrition (TPN) supplemented with either soybean oil (SO 1.0 g/kg body weight daily, n = 20) for 5 days or a combination of FO and SO (FO 0.2 + SO 0.8 g/kg body weight daily, n = 24). Compared to pure SO supplementation in the postoperative period, FO significantly reduced ASAT [0.8 +/- 0.1 vs. 0.5 +/- 0.1 mmol/(l. sec)], ALAT [0.9 +/- 0.1 vs. 0.6 +/- 0.1 mmol/(l. sec)], bilirubin (16.1 +/- 5.3 vs. 6.9 +/- 0.6 mmol/l), LDH (7.7 +/- 0.4 vs. 6.7 +/- 0.4 mmol/(l. sec) and lipase (0.6 +/- 0.1 vs. 0.4 +/- 0.1 micromol/(l. sec) in the postoperative course. Moreover, patients with increased risk of sepsis (IL-6/IL-10 ratio >8) showed a tendency to shorter ICU stay (18 hr) under omega-3 PUFA treatment. Weight loss as encountered after the SO emulsion of 1.1 +/- 2.2 kg was absent in the FO group. After major abdominal tumor surgery, FO supplementation improved liver and pancreas function, which might have contributed to the faster recovery of patients. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15239141     DOI: 10.1002/ijc.20291

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

1.  Docosahexaenoic acid reduces suppressive and migratory functions of CD4+CD25+ regulatory T-cells.

Authors:  Akadiri Yessoufou; Aude Plé; Kabirou Moutairou; Aziz Hichami; Naim Akhtar Khan
Journal:  J Lipid Res       Date:  2009-06-27       Impact factor: 5.922

Review 2.  Nutrition in Pancreatic Cancer: A Review.

Authors:  Simone Gärtner; Janine Krüger; Ali A Aghdassi; Antje Steveling; Peter Simon; Markus M Lerch; Julia Mayerle
Journal:  Gastrointest Tumors       Date:  2016-01-08

3.  Improved fatty acid and leukotriene pattern with a novel lipid emulsion in surgical patients.

Authors:  Helmut Grimm; Norbert Mertes; Christiane Goeters; Ewald Schlotzer; Konstantin Mayer; Friedrich Grimminger; Peter Fürst
Journal:  Eur J Nutr       Date:  2005-07-22       Impact factor: 5.614

4.  n-3, n-6, and n-9 polyunsaturated fatty acids--which composition in parenteral nutrition decreases severity of acute hemorrhagic necrotizing pancreatitis in rats?

Authors:  M Kilian; I Heukamp; J I Gregor; C Bretthauer; M K Walz; C A Jacobi; H Lochs; I Schimke; H Guski; F A Wenger
Journal:  Int J Colorectal Dis       Date:  2005-04-29       Impact factor: 2.571

Review 5.  Nutritional considerations after gastrectomy and esophagectomy for malignancy.

Authors:  Amelia Baker; Leigh-Anne Wooten; Michele Malloy
Journal:  Curr Treat Options Oncol       Date:  2011-03

6.  Preclinical Evaluation of the Short-Term Toxicity of 4-(N)-Docosahexaenoyl 2´, 2´- Difluorodeoxycytidine (DHA-dFdC).

Authors:  Solange Valdes; Youssef W Naguib; Rick A Finch; Wallace B Baze; Christopher A Jolly; Zhengrong Cui
Journal:  Pharm Res       Date:  2017-03-28       Impact factor: 4.200

Review 7.  Parenteral fish oil lipid emulsions in the critically ill: a systematic review and meta-analysis.

Authors:  William Manzanares; Rupinder Dhaliwal; Brian Jurewitsch; Renee D Stapleton; Khursheed N Jeejeebhoy; Daren K Heyland
Journal:  JPEN J Parenter Enteral Nutr       Date:  2013-04-22       Impact factor: 4.016

Review 8.  Multi-targeted therapy of cancer by omega-3 fatty acids.

Authors:  Isabelle M Berquin; Iris J Edwards; Yong Q Chen
Journal:  Cancer Lett       Date:  2008-05-13       Impact factor: 8.679

9.  Impact of postoperative omega-3 fatty acid-supplemented parenteral nutrition on clinical outcomes and immunomodulations in colorectal cancer patients.

Authors:  Bin Liang; Shan Wang; Ying-Jiang Ye; Xiao-Dong Yang; You-Li Wang; Jun Qu; Qi-Wei Xie; Mu-Jun Yin
Journal:  World J Gastroenterol       Date:  2008-04-21       Impact factor: 5.742

Review 10.  Alternative lipid emulsions in the critically ill: a systematic review of the evidence.

Authors:  William Manzanares; Rupinder Dhaliwal; Brian Jurewitsch; Renee D Stapleton; Khursheed N Jeejeebhoy; Daren K Heyland
Journal:  Intensive Care Med       Date:  2013-06-29       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.